Back To Search Results

Typhoid Vaccine

Editor: Mahmoud Shorman Updated: 7/1/2024 11:51:51 PM

Indications

While typhoid fever is uncommon in the United States, its causative agent, Salmonella enterica serotype Typhi (Typhi), is one of the world's leading infectious public health threats. The bacteria is endemic to Africa, Latin America, and Asia, particularly in the southern region of this continent. S Typhi causes 11 to 20 million infections and 128,000 to 161,000 deaths annually, primarily in children.[1] This bacterium is endemic to many low and middle-income countries with poor water, sanitation, and hygiene infrastructure. Forty-four countries, primarily in Africa and Asia, have infection rates exceeding 100 per 100,000 person-years.[2] High rates of enteric fever exact significant personal, community, healthcare, and economic costs in endemic countries.

Most S Typhi or S Paratyphi infections in the United States and other high-income countries (HICs) occur during travel to countries where the infection is endemic or contact with persons infected with S Typhi. Approximately 400 people in the United States develop typhoid fever every year. International travel, mainly to India or Pakistan, accounts for 85% of cases, with visiting friends and family as the primary reason for travel.[24] Less than 6% of patients with Salmonella Typhi infections received a typhoid vaccine in the previous 5 years. Localized transmission or outbreaks occur annually in the United States and primarily originate from ill or convalescent household members or a food handler who is an asymptomatic carrier.

Vaccination in the United States and Other Nonendemic Countries

The United States Advisory Committee for Immunization Practice (ACIP) and the Center for Disease Control's 2024 Yellow Book indicate vaccination for the following individuals:

  • Individuals traveling to endemic areas, particularly to South Asia, and those with health or travel-related risks traveling to other endemic countries. These individuals include children, travelers who are visiting friends and relatives (even for short stays), people who have spent (or are currently spending) months or longer traveling, patients with anatomical or functional asplenia, receiving acid suppressant therapy, or people who wish to be vaccinated.[25]
  • Individuals with intimate exposure (eg, household contact) to a person documented to be a chronic carrier of Salmonella Typhi.[3]
  • Individuals working in a laboratory setting with specimens that may be typhoid-contaminated.[3]

The United States Food and Drug Administration (FDA) has approved 2 unconjugated vaccines to prevent Salmonella Typhi infection in the United States: an oral attenuated live virus vaccine (Ty21a) and an injectable Vi-capsular polysaccharide vaccine (ViPS or ViCPS).

  • The oral Ty21a vaccine (Vivotif, Emergent Biosolutions) was first licensed in Europe in 1983 and the United States in 1989 and is FDA-approved for adults and children older than 6. This vaccine series consists of 4 capsules, each taken every 2 days. ACIP recommends updating the Ty21a vaccine every 5 years with the entire 4-dose series for patients with continuous or recurrent possible exposure to S Typhi.[3] Other countries recommend a 3-capsule series and repeated vaccination every 1 to 7 years.[4]
  • The ViPS vaccine is available in several dosage forms and was first licensed in the United States in 1994. The FDA has approved the ViPS vaccine for adults and children aged 2 and older. ACIP recommends administering booster vaccines every 2 years if the risk for S Typhi continues or recurs.[25] The WHO recommends booster vaccines every 3 years.[4]

ACIP does not recommend the typhoid vaccine for routine immunization in the United States.[5] Many nonendemic countries have recommendations similar to those of the United States (eg, Canada and Europe). Clinicians should follow country-specific recommendations.[4] As Salmonella Typhi infection confers incomplete immunity, patients with a history of typhoid infection require vaccination according to the same criteria as those with no prior infection.[25]

Vaccination in Endemic Countries

The World Health Organization (WHO) recommends typhoid vaccines as part of routine immunization programs to prevent and control typhoid fever in endemic countries. Implementation priority is given to countries with a high burden of typhoid disease or multidrug-resistant S Typhi.[4] The typhoid vaccine is ideally administered during infancy. Catch-up vaccination may be administered to patients aged 15 and younger if available, and the decision is supported by epidemiological evidence. Typhoid conjugate vaccines (TCVs) are preferred in endemic countries.[4] As of February 2024, the WHO has prequalified 3 TCVs; other TCVs are undergoing the WHO prequalification process or are licensed in individual countries. TCV vaccines are not licensed in the United States or other nonendemic countries.

  • Typbar-TCV® (Bharat BioNtech International Ltd, India; prequalified December 2017) can be administered to children 6 months and older and adults aged 45 and younger. The WHO recommends an initial dose at 9 months, coadministered with other routine vaccines or before age 2.[4]
  • TyphiBevTM (Biological E Ltd, India; prequalified December 2020) may be administered to patients 6 months to 45 years.[26]
  • SKYTyphoidTM (SK Bioscience Co. Ltd, South Korea; prequalified February 2024) is safe and effective for patients 6 months to 45 years.[6]

As with vaccination in nonendemic countries, patients with a history of typhoid infection require primary immunization according to the same criteria as those with no prior infection. The optimal TCV booster schedule across age groups is undetermined.

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Unconjugated Typhoid Vaccines

Ty21a vaccine: The live attenuated Ty21a strain lacks uridine-diphosphate-galactose-4-epimerase, resulting in the inability to manufacture Vi polysaccharide and a cytoplasmic accumulation of galactose that eventually causes cell lysis.[7] This vaccine induces the production of serum and intestinal mucosal antibodies against O, H, and other surface antigens but not against the Vi polysaccharide. The strength of the initial response mediated by IgA antibody-secreting cells and the presence of anti-O immunoglobulin G antibodies are the best markers of protection.[4] A long-lasting cell-mediated immunity develops and includes a specific cytotoxic T-lymphocyte response.

The Ty21a vaccine has a cumulative efficacy of 43% (CI 30%-53%; 4 trials) over 1 to 5 years of follow-up among participants aged 3 to 44.[1] The patient's age during vaccination does not affect this efficacy. Other oral vaccines, such as Rotarix, polio, and cholera, demonstrate poor efficacy in low and middle-income countries (LMIC) due to various factors, including higher rates of concomitant gastrointestinal disease, microbial dysbiosis, and mucosal tolerance.[1] The Ty21a vaccine may be more effective for the populations of high-income countries, but no evidence exists to support this. Maximum effectiveness requires taking all doses.

ViPS vaccine: Immunization initially induces increased production of IgG anti-Vi antibodies, which are found in elevated levels in the serum. The immune system develops an immunologic memory in response to ViPS vaccination, as polysaccharide antigens do not induce T-cell production. Antibody titer levels decline significantly by the third year after immunization.[4] This vaccine has an estimated cumulative efficacy of 57% (CI 44%-69%; 5 trials) over 1 to 3 years among participants aged 2 to 50.[1] The patient's age is unlikely to affect vaccine efficacy, although insufficient power and a large margin of uncertainty of vaccine efficacy in children younger than 5 may obscure any significant differences.[4]

Typhoid Conjugate Vaccines

All TCVs contain 25 μg of Vi polysaccharide conjugated with a protein carrier. This carrier component engages B and T-cells, inducing germinal center development in the spleen and lymph nodes. Within germinal centers, polysaccharide-specific B-cells proliferate and differentiate through hypermutation of the antibody genes. Follicular helper T-cells aid this process once activated by the protein carrier presented by the major histocompatibility complex on the B-cell surface.[8] An increased affinity of the B-cell receptor antibody to the antigen increases the aid provided by T-cells via cytokines and direct cell-to-cell interaction. Repeated cycles produce higher-affinity antibodies and antibody class switching, similar to the immune response during a typical infection. B-cells in germinal centers that do not engage T-cells undergo apoptosis.[8]

Along with a 2024 systematic review and meta-analysis, new randomized controlled trials (RCTs) studying the efficacy of typhoid vaccines for preventing culture-confirmed S Typhi infection support the results reported in previous reviews, such as the 2018 Cochrane Review. These study data include newer conjugate vaccines and extended observation periods.[1][9][10] The systematic review found no RCTs studying typhoid vaccine efficacy in populations of nonendemic countries; all data are from studies in endemic countries.[1] RCTs studying the efficacy of conjugated vaccines are few but growing in number. An update to the 2018 Cochrane Review of Typhoid Vaccines is pending; a protocol was registered with the Cochrane Library in March 2023.[26] This update will focus solely on TCVs. Human challenge and other immunogenicity studies provide additional evidence of vaccine efficacy, cited here for vaccines without efficacy data.

ViTT vaccines: The Vi-tetanus toxoid conjugate (Vi-TT) vaccine is conjugated with a nontoxic tetanus toxoid carrier.[26] Vi-TT is available in 2 formulations: Typbar-TCV® and PedaTyphTM (BioMed, India). A single dose of the Typbar-TCV® Vi-TT vaccine has a cumulative efficacy of 83% (CI 77% to 88%; 4 trials) 1 to 2 years post-immunization in infants and children aged 6 months to 16 years.[1] The most recent Typbar-TCV® Vi-TT vaccine trial analysis in Malawian children aged 9 months to 12 years showed an efficacy of 78.3% (CI 66.3% to 86.1%) 4 years after a single dose.[9] Differences in efficacy were nonsignificant across age groups.

In an outbreak setting, the Typbar-TCV® Vi-TT vaccine demonstrated 95% effectiveness (93% to 96%) against culture-confirmed S Typhi in children aged 6 months to 10 years during a study conducted from February 21, 2018, to December 31, 2019, in Hyderabad, Pakistan.[11] Despite only moderate deployment, this vaccine curtailed the outbreak. An alternate formulation of Vi-TT (PedaTyphTM) is licensed and marketed only in India.[4] This vaccine can be administered to children 3 months or older.[26] The 2018 Cochrane review reported an efficacy of 94% (CI 0%-101%) based on a single study. The actual effect is uncertain due to a wide confidence interval and a lack of unclustering during statistical analysis of the study data.[12]

Vi-CMR197 vaccine

TyphiBevTM is a Vi-CMR197 conjugate vaccine comprising a Vi protein attached to a mutant nontoxic diphtheria toxoid. Vi-CMR197 is non-inferior to the Vi-TT vaccine and demonstrates a seroconversion rate of 99.0% (CI 97.1% to 97.6%) versus 99.3% (CI 97.6% to 99.9%) for Vi-TT based on a seroconversion threshold of 2 μg/mL.[13] Immunogenicity response rates were consistent across age ranges from 6 months to 54 years. The serum geometric mean titers (GMTs) of anti-Vi IgG antibodies induced by Vi-CMR197 and Vi-TT were comparable overall and across age ranges.[13]

Vi-Diphtheria toxoid vaccine

SKYTyphoid® is a Vi-diphtheria toxoid vaccine (Vi-DT). The Vi-DT seroconversion rate of 99.7% (97.5%, CI 98.0% to 100.0%) is non-inferior to Vi-TT vaccination (99.1%, CI 94.3% to 100.0%) in participants aged 6 months to 45 years during a phase 3 trial based on a seroconversion threshold of 0.14 μg/mL.[6] No differences were observed across age strata. The anti-Vi IgG GMTs showed no differences across age strata compared to Vi-TT. However, significant differences occurred in participants aged 6 to 24 months; this group had more adverse effects and a significantly lower mean GMT compared to Vi-TT (50.2 vs 73.4 IU/mL) at 24 months.[6] Further study is needed to elaborate on this finding.

Vi-rEPA vaccine

Vi-rEPA is an early TCV conjugated with a recombinant exoprotein A from Pseudomonas aeruginosa. The efficacy of Vi-rEPA is 89% (CI 77%-95%; 1 trial) for 4 years post-administration of 2 vaccine doses.[1] Relevant studies did not include children younger than 2.[12] This vaccine is not commercially available.

Administration

Unconjugated Vaccines

Ty21a: Vaccination requires 4 oral enteric-coated capsules, each taken 48 hours apart. Each capsule is taken 1 hour before or at least 2 hours after a meal with water cooler than body temperature (≤37.0 °C). The capsules must be refrigerated until use. The patient must complete this series at least 1 week before a potential exposure.[25]

ViPS: Vaccination requires a single 0.5 mL (25 μg) intramuscular dose at least 2 weeks before a potential exposure.[25]

Typhoid Conjugate Vaccines

All TCVs require a single intramuscular dose, except for the PedaTyphTM and Vi-rEPA vaccines, which require a 2-dose primary series separated over 4 to 8 weeks.[4] The optimal booster schedules for most TCVs remain undefined and depend on factors such as the vaccination age and the degree of natural boosting in the individual patient.[4][14] The manufacturer recommends an initial PedaTyphTM immunization for infants aged 3 to 23 months, a booster at 24 to 30 months, and boosters every 10 years afterward.[26]

Coadministration With Other Vaccines

The Ty21a and ViPS vaccines can be administered with other travel or childhood vaccines, including live ones. Likewise, TCVs can be administered safely with other childhood vaccines, as demonstrated by the Malawi and Burkina Faso studies. Specifically, measles-rubella vaccines are safe and effective when administered at 9 and 15 months, yellow fever vaccine at 9 months, and meningococcal vaccine at 15 months.[14] Several recent and ongoing TCV study protocols require the concurrent administration of the study vaccine and routine childhood vaccines.[12]

Adverse Effects

Typhoid vaccines currently in use are safe and generally well tolerated. They may cause mild local or systemic adverse effects. However, study data shows these effects are similar to those caused by placebo or comparator vaccines used in trials (meningococcal, hepatitis, pneumococcal, or other TCV). Multiple studies report no serious adverse events associated with TCVs to date.[1][6][1][12][10][12][13][15]

Each vaccine is associated with specific adverse events:

  • The oral Ty21a vaccine is commonly associated with fever compared to placebo.[12] Vomiting, diarrhea, nausea, and abdominal pain occur with similar frequency as with placebo.
  • ViPS is commonly associated with injection site swelling and pain compared to placebo.[12]
  • Vi-rEPA is associated with increased rates of fever after each vaccine dose. Swelling at the injection site was more common after the second dose compared to placebo.[12]

Contraindications

Pregnant and Lactating Women

Safety data for typhoid vaccine administration to pregnant and lactating women is lacking for all vaccines. The ViPS vaccine and TCVs are thought to have minimal or absent risk.[4] These can be safely administered if indicated.[4] [16]Live vaccines are not recommended during pregnancy due to theoretical risks to the pregnant woman or fetus.[4] The CDC recommends against administering Ty21a to pregnant women and avoiding conception until 4 weeks after immunization.[25]

Concurrent Conditions or Medications

The CDC recommends the ViPS vaccine for patients who are immunocompromised.[25] The ViPS vaccine and TCVs may be safely administered to patients who are immunocompromised, including those with HIV. However, an immunocompromised patient may demonstrate reduced production of protective antibodies following non-live typhoid vaccinations. This phenomenon is pronounced in patients who are severely immunocompromised due to conditions (eg, symptomatic human immunodeficiency virus/acquired immunodeficiency syndrome, chronic lymphocytic leukemia, hematopoietic stem cell transplant, generalized cancer) or receiving immunosuppressive medications (eg, alkylating agents, antimetabolites, biologic agents. In patients with HIV, antibody induction with ViPS and TCVs correlates directly to the CD4+ count.[25]

The CDC also recommends against administering the live Ty21a vaccine to individuals with a known suppression of cell-mediated immunity, who have been receiving high-dose steroid therapy for 2 weeks or longer, or who are receiving chemotherapeutic or radiation therapy.[25] The WHO considers Ty21a safe to administer to patients with HIV and a CD4+ count of 200 cells/mm3 or greater (CD4+ >25% in children younger than 5).[4] The immunogenicity of TY21a may be reduced in patients with acute severe gastrointestinal conditions; immunization for these patients should be delayed until after recovery. Other minor illnesses are not contraindications for these vaccines, although some individuals choose to delay vaccination until after recovery. Antibiotics may reduce immunogenicity, and concurrent administration with the Ty21a vaccine should be avoided. Various monoclonal antibodies may also interfere with antibody production. An allergic reaction to any vaccine (or any of its components) is a contraindication for that vaccine.

Monitoring

No monitoring or routine testing is necessary with any of the vaccines described.

Toxicity

There is no toxicity associated with any typhoid vaccination formulation in the literature.

Enhancing Healthcare Team Outcomes

Understanding the rationale for using various typhoid vaccines is critical to providing optimal care to people at risk of typhoid infection in endemic and nonendemic countries. Knowledge of the presentation of enteric fever, diagnostic and treatment challenges, the rise of antimicrobial resistance, and implementation considerations aid healthcare providers in making healthcare recommendations regarding vaccination. This knowledge is also necessary to improve the implementation of vaccination programs and widespread prevent enteric illness.

Presentation and Diagnosis

Clinicians must advise healthy patients living in or traveling to endemic countries of the risk of S Typhi infection, its associated risk factors, early signs and symptoms, and when and how to seek help should they become ill. Practitioners must also monitor for early signs and symptoms of the disease in patients with typhoid fever to avoid complications and possible death.

Salmonella enterica serotype Typhi is a pathogen found only in humans. S Typhi is ingested through contaminated food or water, particularly in areas with inadequate WASH infrastructure. The bacteria can withstand stomach acid and penetrate the small bowel's epithelial enterocytes or lymphoid tissue. S Typhi is primarily spread by intracellular lymphatic and hematogenous routes. During typhoid challenge studies, patients develop a complex immune response to multiple bacterial antigens; those who become clinically ill do not develop antibodies to the Vi capsular polysaccharide of S Typhi.[17] The closely related Salmonella enterica serotypes Paratyphi A, B, and C (S Paratyphi) cause an illness clinically indistinguishable from Salmonella Typhi infection.[3]

Typhoid and paratyphoid fever are collectively referred to as enteric fever. In endemic areas, enteric fever is frequently confused with other nonspecific febrile illnesses. Following an incubation period of 6 to 30 days, enteric fever initially presents as an undifferentiated, progressive fever that increases with bacteremia. Fatigue, anorexia, headache, malaise, and abdominal symptoms are commonly accompanying symptoms. A faint macular rash on the trunk and abdomen ("rose spots") and hepatosplenomegaly may also occur.

Enteric fever can have severe outcomes, including death. Complications usually arise during the third week of illness; ileocecal perforation, peritonitis, or septic shock occur in 30% of patients who do not receive treatment.[18] Patients may have a protracted recovery lasting weeks or months. The bacteria may be present in the stool for months after infection. Five percent of patients become carriers and excrete S Typhi in the stool for over a year. Relapse of fever occurs in about 10% of untreated patients. Death occurs in 10% to 30% of patients who remain untreated.[18]

Culture from blood, stool, urine, bone marrow, duodenal contents, or skin rash is the gold standard for typhoid fever confirmation. However, blood culture (the most common laboratory testing) has low sensitivity (50% to 66%) for patients in endemic areas and is frequently unavailable in these regions. The sensitivity of blood culture testing is significantly greater (>90%) for travelers.[19] Newer rapid diagnostic tests are becoming increasingly available.

Treatment and Antimicrobial Resistance

The rapid development of S Typhi drug resistance worldwide makes antibiotic therapy challenging.[20] The WHO recommends initial treatment pending culture for patients with suspected enteric fever. Treatment varies between areas with and without known resistance to ciprofloxacin medications. Treatment is a third-generation cephalosporin for severe illness in all areas and a fluoroquinolone antibiotic or azithromycin for milder illness, depending on where the infection was acquired.[27] Knowing the sensitivity pattern for the area where the infection occurred guides initial antibiotic therapy.[21][22] A lack of access to affordable healthcare in many endemic countries, difficulties in diagnosis due to undifferentiated illness, poor diagnostic tools, and potentially severe outcomes contribute to the need for empiric therapy.[14]

The high rates of infection in many endemic countries and the use of empiric treatment place evolutionary pressure on the development of antimicrobial resistance, posing a significant global health threat. S Typhi acquires resistance genes from or transmits genes to other Salmonella species and other microbes. Multidrug-resistant (XDR) strains demonstrate resistance to ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol. The emergence of XDR typhoid in Pakistan in 2016 and its spread to at least 16 other countries is an alarming public health issue.[18] XDR strains also resist third-generation cephalosporins, leaving azithromycin and meropenem as the only effective antibiotics.[14][27][14]

Implementation

Highly effective vaccines are vital in preventing typhoid disease and the development of antimicrobial resistance globally. The first whole-cell typhoid vaccines emerged during the late 19th century but were associated with a high rate of severe side effects. Safe and effective unconjugated vaccines replaced these in the 1990s. However, unconjugated vaccines confer insufficient immunity to effectively prevent illness and outbreaks in endemic countries. The need for multiple doses and a limited age range for administering the Ty21a vaccine further limits the usefulness of this vaccine type in the most affected populations.

TCVs are changing the landscape of typhoid prevention and are now one of many routine childhood vaccines in highly endemic countries. They are also used to quell typhoid outbreaks. For example, TCV was effective in limiting an XDR outbreak in Pakistan in 2018 and 2019 that affected 14,984 people. Due to their importance in preventing XDR typhoid, TCVs are on the WHO list of essential medicines for priority diseases.[1]

Nonendemic countries

In non endemic countries, including the United States, healthcare workers who provide primary care and vaccines to, or are in contact with, travelers must be aware of the increased risk of enteric and other illnesses. These travelers should also be informed of the increased risk of enteric infection if they visit certain regions. Nurse practitioners, primary care physicians, and pharmacists should direct patients to local health units or other practitioners who provide travel advice. Healthcare practitioners administering the vaccine should understand the indications, contraindications, and proper administration.

Travelers from nonendemic countries must understand that the typhoid vaccine prevents approximately 50% to 66% of typhoid fever infections. Immunization against S Typhi does not prevent paratyphoid fever or other gastrointestinal illnesses and does not preclude the need for food and water safety precautions, amongst other health measures. Frequent hand-washing and avoiding the local water supply and certain foods are critical.

Endemic countries

Collaboration between physicians, nurses, pharmacists, public and community health workers, and civil society partners is essential to implement typhoid vaccine programs effectively. Accurate assessments of typhoid epidemiology and other critical health issues, funding and secure vaccine supply, community trust building, safe transport, storage and administration of vaccines, and follow-up for adverse events are necessary for optimal program implementation. All TCVs require strict cold chain maintenance.

The WHO gives the highest priority for TCV use to highly endemic countries and those with high rates of XDR typhoid.[4] TCVs are preferred by the WHO to prevent typhoid fever due to their immunological properties, efficacy in young children, and prolonged duration of immunity compared to unconjugated vaccines.[4] Previously, only Typbar-TCV® was WHO-prequalified, raising supply concerns. Since then, Vi-CMR197TM and SKYTyphoidTM have become prequalified. A stable and cost-effective vaccine supply requires multiple vaccine types and manufacturers; several newer vaccines are at various stages of development.[14] The Vi-rEPA vaccine is not currently commercially available.

As of June 2024, 6 countries have incorporated TCV into their routine immunization schedules in combination with WASH interventions.[23] Several other countries are currently in the application or implementation process. Distribution is handled by international agencies such as the internationally-funded Gavi Global Vaccine Alliance.[23] In addition to S Typhi vaccination, effective prevention of enteric fever requires a separate vaccine to prevent S Paratyphi. While the Ty21 vaccine demonstrates some cross-reactivity for Salmonella Paratyphi B, it does not confer sufficient immunity to be used clinically for S Paratyphi B prevention and is not FDA-approved for this purpose.[25] Improved diagnostic tools, water, sanitation, and hygiene infrastructure are essential to eliminate enteric fever as a global health threat. 

Other Prevention Measures 

Preventing typhoid fever and other enteric illnesses requires safe food and water practices and infrastructure. For travelers and people living in risk areas, washing hands before eating, eating foods thoroughly cooked and served hot, and eating personally peeled fruits are essential safeguards. Drinking water should be boiled, chemically disinfected, or bottled and personally opened. Adequate water, sanitation, and hygiene (WASH) infrastructure is vital to decrease the incidence of typhoid fever in endemic countries. Developing an S Paratyphi vaccine is critical in the global fight against enteric fever and antimicrobial resistance, particularly in countries where S Paratyphi comprises a large part of the enteric fever burden.

References


[1]

Batool R, Qamar ZH, Salam RA, Yousafzai MT, Ashorn P, Qamar FN. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis. The Lancet. Global health. 2024 Apr:12(4):e589-e598. doi: 10.1016/S2214-109X(23)00606-X. Epub     [PubMed PMID: 38485426]

Level 1 (high-level) evidence

[2]

GRAM Typhoid Collaborators. Estimating the subnational prevalence of antimicrobial resistant Salmonella enterica serovars Typhi and Paratyphi A infections in 75 endemic countries, 1990-2019: a modelling study. The Lancet. Global health. 2024 Mar:12(3):e406-e418. doi: 10.1016/S2214-109X(23)00585-5. Epub     [PubMed PMID: 38365414]


[3]

Jackson BR, Iqbal S, Mahon B, Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015. MMWR. Morbidity and mortality weekly report. 2015 Mar 27:64(11):305-8     [PubMed PMID: 25811680]


[4]

World Health Organization, Typhoid vaccines: WHO position paper, March 2018 - Recommendations. Vaccine. 2019 Jan 7     [PubMed PMID: 29661581]


[5]

Britto CD, Wong VK, Dougan G, Pollard AJ. A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid. PLoS neglected tropical diseases. 2018 Oct:12(10):e0006779. doi: 10.1371/journal.pntd.0006779. Epub 2018 Oct 11     [PubMed PMID: 30307935]

Level 1 (high-level) evidence

[6]

Kumar Rai G, Saluja T, Chaudhary S, Tamrakar D, Kanodia P, Giri BR, Shrestha R, Uranw S, Kim DR, Yang JS, Park IY, Kyung SE, Vemula S, Reddy E J, Kim B, Gupta BP, Jo SK, Ryu JH, Park HK, Shin JH, Lee Y, Kim H, Kim JH, Mojares ZR, Wartel TA, Sahastrabuddhe S. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. The Lancet. Infectious diseases. 2022 Apr:22(4):529-540. doi: 10.1016/S1473-3099(21)00455-2. Epub 2021 Dec 20     [PubMed PMID: 34942090]

Level 1 (high-level) evidence

[7]

Amicizia D, Arata L, Zangrillo F, Panatto D, Gasparini R. Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®). Journal of preventive medicine and hygiene. 2017 Mar:58(1):E1-E8     [PubMed PMID: 28515625]

Level 3 (low-level) evidence

[8]

Rappuoli R, De Gregorio E, Costantino P. On the mechanisms of conjugate vaccines. Proceedings of the National Academy of Sciences of the United States of America. 2019 Jan 2:116(1):14-16. doi: 10.1073/pnas.1819612116. Epub 2018 Dec 21     [PubMed PMID: 30578318]


[9]

Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA, TyVAC team. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet (London, England). 2024 Feb 3:403(10425):459-468. doi: 10.1016/S0140-6736(23)02031-7. Epub 2024 Jan 25     [PubMed PMID: 38281499]

Level 1 (high-level) evidence

[10]

Mohamed Taha A, Abouelmagd K, Mahmoud AM, Elkasaby MH, Nguyen D, Ahmed R, Patel P, Bonilla-Aldana DK, Luna C, Rodriguez-Morales AJ. Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2 years: a systematic review and meta-analysis. Frontiers in microbiology. 2024:15():1385834. doi: 10.3389/fmicb.2024.1385834. Epub 2024 Apr 5     [PubMed PMID: 38646637]

Level 1 (high-level) evidence

[11]

Yousafzai MT, Karim S, Qureshi S, Kazi M, Memon H, Junejo A, Khawaja Z, Ur Rehman N, Ansari MS, Ali R, Ujjan IU, Lohana HM, Memon NM, Hussain M, Nigar R, Bar-Zeev N, Qamar FN. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. The Lancet. Global health. 2021 Aug:9(8):e1154-e1162. doi: 10.1016/S2214-109X(21)00255-2. Epub     [PubMed PMID: 34297962]


[12]

Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. The Cochrane database of systematic reviews. 2018 May 31:5(5):CD001261. doi: 10.1002/14651858.CD001261.pub4. Epub 2018 May 31     [PubMed PMID: 29851031]

Level 1 (high-level) evidence

[13]

Thuluva S, Paradkar V, Matur R, Turaga K, Gv SR. A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator. Human vaccines & immunotherapeutics. 2022 Nov 30:18(5):2043103. doi: 10.1080/21645515.2022.2043103. Epub 2022 Mar 25     [PubMed PMID: 35333702]

Level 1 (high-level) evidence

[14]

Nampota-Nkomba N, Carey ME, Jamka LP, Fecteau N, Neuzil KM. Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever. Open forum infectious diseases. 2023 May:10(Suppl 1):S6-S12. doi: 10.1093/ofid/ofad022. Epub 2023 Jun 2     [PubMed PMID: 37274532]


[15]

Tamrakar D, Poudel P, Thapa P, Singh S, Khadgi A, Thapa S, Tamrakar R, Shrestha A, Madhup S, Rai GK, Gupta BP, Saluja T, Sahastrabuddhe S, Shrestha R. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers. Human vaccines & immunotherapeutics. 2024 Dec 31:20(1):2301631. doi: 10.1080/21645515.2023.2301631. Epub 2024 Jan 8     [PubMed PMID: 38189360]

Level 1 (high-level) evidence

[16]

. Typhoid Vaccine. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000191]


[17]

Meiring JE, Khanam F, Basnyat B, Charles RC, Crump JA, Debellut F, Holt KE, Kariuki S, Mugisha E, Neuzil KM, Parry CM, Pitzer VE, Pollard AJ, Qadri F, Gordon MA. Typhoid fever. Nature reviews. Disease primers. 2023 Dec 14:9(1):71. doi: 10.1038/s41572-023-00480-z. Epub 2023 Dec 14     [PubMed PMID: 38097589]


[18]

Marchello CS, Birkhold M, Crump JA. Complications and mortality of typhoid fever: A global systematic review and meta-analysis. The Journal of infection. 2020 Dec:81(6):902-910. doi: 10.1016/j.jinf.2020.10.030. Epub 2020 Nov 2     [PubMed PMID: 33144193]

Level 1 (high-level) evidence

[19]

Parry CM, Qamar FN, Rijal S, McCann N, Baker S, Basnyat B. What Should We Be Recommending for the Treatment of Enteric Fever? Open forum infectious diseases. 2023 May:10(Suppl 1):S26-S31. doi: 10.1093/ofid/ofad179. Epub 2023 Jun 2     [PubMed PMID: 37274536]


[20]

Booth JS, Goldberg E, Patil SA, Barnes RS, Greenwald BD, Sztein MB. Effect of the live oral attenuated typhoid vaccine, Ty21a, on systemic and terminal ileum mucosal CD4+ T memory responses in humans. International immunology. 2019 Feb 15:31(2):101-116. doi: 10.1093/intimm/dxy070. Epub     [PubMed PMID: 30346608]


[21]

Masuet-Aumatell C, Atouguia J. Typhoid fever infection - Antibiotic resistance and vaccination strategies: A narrative review. Travel medicine and infectious disease. 2021 Mar-Apr:40():101946. doi: 10.1016/j.tmaid.2020.101946. Epub 2020 Dec 8     [PubMed PMID: 33301931]

Level 3 (low-level) evidence

[22]

Hughes MJ, Birhane MG, Dorough L, Reynolds JL, Caidi H, Tagg KA, Snyder CM, Yu AT, Altman SM, Boyle MM, Thomas D, Robbins AE, Waechter HA, Cody I, Mintz ED, Gutelius B, Langley G, Francois Watkins LK. Extensively Drug-Resistant Typhoid Fever in the United States. Open forum infectious diseases. 2021 Dec:8(12):ofab572. doi: 10.1093/ofid/ofab572. Epub 2021 Nov 16     [PubMed PMID: 34917695]


[23]

Shakya M, Pollard AJ. Typhoid conjugate vaccines: a step towards typhoid control. The Lancet. Global health. 2024 Apr:12(4):e535-e536. doi: 10.1016/S2214-109X(24)00055-X. Epub     [PubMed PMID: 38485415]